Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
H pylori antibiotic resistance: prevalence, importance, and advances in testing
This map shows the geographic impact of F Mégraud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F Mégraud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F Mégraud more than expected).
This network shows the impact of papers produced by F Mégraud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F Mégraud. The network helps show where F Mégraud may publish in the future.
Co-authorship network of co-authors of F Mégraud
This figure shows the co-authorship network connecting the top 25 collaborators of F Mégraud.
A scholar is included among the top collaborators of F Mégraud based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with F Mégraud. F Mégraud is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Mégraud, F. (2004). H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 53(9). 1374–1384.774 indexed citations breakdown →
3.
Mégraud, F. (2003). [Helicobacter pylori, gastric inflammation and its consequences].. PubMed. 61(4). 282–7.3 indexed citations
4.
Mauget‐Faÿsse, Martine, et al.. (2002). [Helicobacter pylori in central serous chorioretinopathy and diffuse retinal epitheliopathy. Results of the first prospective pilot study].. PubMed. 25(10). 1021–5.34 indexed citations
5.
Lamouliatte, H, et al.. (2000). [Treatment of Helicobacter pylori infection].. PubMed. 50(13). 1442–5.2 indexed citations
6.
Mégraud, F & Nathalie Broutet. (2000). [Epidemiology, acquisition and transmission of Helicobacter pylori].. PubMed. 50(13). 1414–7.10 indexed citations
Heikkinen, M., et al.. (1997). Usefulness of anti-Helicobacter pylori and anti-CagA antibodies in the selection of patients for gastroscopy.. PubMed. 92(12). 2225–9.25 indexed citations
11.
Occhialini, Alessandra, María C. Urdaci, Florence Doucet‐Populaire, et al.. (1996). O: Oral presentations. Gut. 39(Suppl 2). A1–A3.1 indexed citations
12.
Mégraud, F, et al.. (1996). Helicobacter pylori: techniques for clinical diagnosis and basic research..49 indexed citations
13.
Mégraud, F, et al.. (1995). [Helicobacter pylori and azithromycin].. PubMed. 43(6). 555–60.9 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.